Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

26 févr. 2024 07h00 HE | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Announces Plan to Resubmit NDA for Etripamil for the Treatment of PSVT

Resubmission of NDA expected 2Q2024 Operating Runway Extended Into Mid-2025 with Cash Conservation Measures MONTREAL and CHARLOTTE, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Milestone®...
26 déc. 2023 07h00 HE | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

MONTREAL and CHARLOTTE, N.C., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) announced today that the Company received a Refusal to File (RTF) letter from the U.S....
05 mars 2012 08h00 HE | Source: Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Appoints Paul Truex to the Board of Directors

MONTREAL, March 5, 2012 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc., a cardiovascular drug development company, today announced the appointment of Paul F. Truex to its Board of Directors. Mr....